Addmedica   Report issue

For profit Phase 4
Founded: Paris France (2005)
Status: No NME R&D (2005)

Organization Overview

First Clinical Trial
2015
NCT02522104
First Marketed Drug
2017
hydroxyurea (hydrea)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

ADDMEDICA SAS | ADDMEDICA SASA

Active Ingredients

Marketed Drugs (1)

hydroxyurea (hydrea) (2017)

Drugs in Phase 4 Trials (1)

hydroxyurea (hydrea) (5 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Albuminuria (Phase 2)

Anemia, Sickle Cell (Phase 4)

Retinal Vein Occlusion (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 5
  • # of Trial APIs: 1